Provides a scathing critique of the chemotherapy culture as well as of unscientific "alternative" therapies and endorses molecularly based technologies, making it an illuminating and necessary read for anyone interested in cancer research, especially patients and their families and physicians.

In 1998 Neil Ruzic was diagnosed with mantle-cell lymphoma, the deadliest cancer of the lymph system. Unhappy with the success rates of standard chemotherapy and radiation treatments, Ruzic took control of his destiny and began to investigate the cutting-edge cures being developed in research laboratories. Going on the offensive, Ruzic visited scores of laboratories, talked to researchers, gathered information, and effectively became his own patient-care advocate. Racing to a Cure provides a scathing critique of the chemotherapy culture as well as of unscientific "alternative" therapies and endorses state-of-the-art, molecularly based technologies, making it an illuminating and necessary read for anyone interested in cancer research, especially patients and their families and physicians. Although expected to die within two years of his initial diagnosis, Neil Ruzic survived for more than five years before the cancer returned and claimed his life in January 2004. David Ruzic has added new material to this edition to explain the most recent cancer therapies for mantle-cell lymphoma as well as celebrate his father's achievements in extending his life, exploding myths about cancer, and setting precedents for patients wanting more from their treatment.